Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anrotinib plus capecitabine for second-line or later HER2-negative advanced breast cancer
ChiCTR2000031388Phase 4Not yet recruiting
- Sponsor
- Chongqing University Affiliated Three Gorges Hospital
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anlotinib and capecitabine in breast cancer (2 arms), sponsored by Chongqing University Affiliated Three Gorges Hospital. Primary endpoint: Progression-free survival. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
anlotinibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000031388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031388.